Other articles

EuroPCR 2022

EuroPCR 2022 | CLASP TR Study: Promising Results of Endovascular Intervention of Tricuspid Regurgitation

EuroPCR 2022 | CLASP TR Study: Promising Results of Endovascular Intervention of Tricuspid Regurgitation

At present, we are well aware of the rise in mortality caused by severe tricuspid regurgitation (TR). Medical and surgical treatments have turned out to be suboptimal. Hence, endovascular intervention presents as an alternative therapeutic strategy with promising results.  The aim of this multicenter, prospective study was to assess the safety and efficacy of the

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | Real World Outcomes on Edge-to-Edge Tricuspid Valve Repair: 30 Day Outcomes of the TriClip bRight

This study was carried out to assess the safety and efficacy of the TriClip (edge-to-edge repair) in patients with severe tricuspid regurgitation with persistent symptoms despite medical treatment and high surgical risk.  It is a prospective multicenter single arm study including 300 patients of mean age 78±7.6; 7.7% presented prior aortic intervention and 28% prior

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | TriCLASP, Evolution at 30 Days

Tricuspid regurgitation (TR) is difficult to manage and is a mortality predictor. At present, surgery is recommended, even though its mortality rate is not low.  Endovascular intervention of this entity is currently being developed and according to the European guidelines, it has evidence level IIb C in symptomatic inoperable patients. The TriCLASP included 74 patients

EuroPCR 2022 | Cambios en el daño cardíaco luego del reemplazo valvular aórtico por cirugía

EuroPCR 2022 | 1 Year Outcomes of Tricuspid Valve Repair with Cardioband: Feasibility Study

Tricuspid failure is a prevalent valvulopathy most often mistreated. It has been associated with high surgical risk and medical treatment has showed substandard therapeutic effect. Surgical repair with valve annuloplasty is the technique of choice for its long-term durability. Transcatheter repair of the tricuspid valve is an alternative that aims at imitating annuloplasty by reducing

ACC 2022

ACC 2022 | CLASP TR Study: Tricuspid Valve Repair with the PASCAL Device

The study included 65 patients who received endovascular treatment of the tricuspid valve with the PASCAL device. Forty-six completed the 12-month follow-up. At 1-year follow-up, the major events endpoint was 16.9%; the most frequent event was bleeding (9.2%). In addition, there were three cases of stroke, one reintervention, two vascular access complications, and five cardiovascular-related

Tavi en pacientes com bajo flujo, bajo gradiente clásico

TRICENTO: Promising Results for Severe Tricuspid Valve Regurgitation

Difficult to treat, tricuspid valve failure poses great medical challenge. In addition, the mortality rate of surgical treatment these days is not exactly low, involving high risk, which often takes this alternative off the table.   Several percutaneous devices have been developed to treat this disease, the most popular being edge-to-edge devices.  The TRICENTO has an

autoexpandible

The FDA Approves Sapien 3 with Alterra in Pulmonary Position

The US Food and Drug Administration (FDA) has cleared the SAPIEN 3 valve with the Alterra adaptive pre-stent for implantation in pulmonary position.  According to Edwards Lifesciences, this new system developed for pulmonary valve is capable of compensating a wide variety of sizes and morphologies of the right ventricular outflow tract, allowing for stable valve implantation.

AHA 2021 | PALACS: la pericardiotomía posterior izquierda mejora la FA post operatoria

AHA 2021 | PALACS: Posterior Left Pericardiotomy Improves Post-Procedural AF

Posterior left pericardiotomy for the prevention of atrial fibrillation during cardiac surgery seems to significantly reduce atrial fibrillation risk (AF) after procedure. The procedure consists of a 4-5 cm incision in the posterior pericardium to allow drainage of fluids and thrombi from the pericardium to the pleural cavity during postoperative period.  Patients receiving the incision during surgery

Miocardiopatía hipertrófica: análisis de una serie histórica

Differences in American and European Atrial Fibrillation Guidelines

The recent publication of the European Society of Cardiology (ESC) and the American College of Cardiology (ACC) guidelines provided an important update on multiple aspects of the management of atrial fibrillation (AF). However, these guidelines differ in terms of management and recommendation levels. As it might be expected, most differences arose in intermediate cases—both guidelines

Nuevas guías de valvulopatías con actualizaciones clave en TAVI e insuficiencia mitral

New Valvular Heart Disease Guidelines with Key TAVI and Mitral Regurgitation Updates

Valvular heart disease management guidelines were updated last week by the AHA and the ACC.  The last complete version had been published in 2014; therefore many of its recommendations have become obsolete before the latest evidence.  The studies that made the FDA approve TAVI for low-risk patients are probably the most important incorporations. They also

marcapasos tavi

Tricuspid valve: Is Percutaneous Intervention Feasible in Patients with Definite Pacemaker?

Courtesy of Dr. Carlos Fava. As we know, with higher life expectancy comes a significant increase in the use of definite pacemakers, defibrillators and resynchronization devices. Along these lines, the presence of catheters is associated to tricuspid regurgitation, which over time might become severe, leading to cardiac regurgitation and potentially heart failure.  This group is

Top